Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Volin

Showing results (101-110 of 131) with videos related to

Pageof 14
Sort By:
Journal of Internal Medicine|October 30, 2018
Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysisJ Canaani, E Beohou, M Labopin, et al.
Annals of Hematology|September 22, 2016
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMTE M P Cremers, A van Biezen, L C de Wreede, et al.
Bone Marrow Transplantation|July 28, 2009
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMTY Chalandon, J R Passweg, C Schmid, et al.
Journal of Internal Medicine|October 14, 2017
What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?O Ringdén, M Labopin, B Sadeghi, et al.
Leukemia|July 17, 1998
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia GroupE Elonen, A Almqvist, A Hänninen, et al.
Bone Marrow Transplantation|January 27, 2004
Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmesS McCann, J L Byrne, M Rovira, et al.
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†S P Robinson, A Boumendil, H Finel, et al.
Bone Marrow Transplantation|June 2, 2015
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMTJ R Passweg, M Labopin, J Cornelissen, et al.
Bone Marrow Transplantation|May 28, 2013
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow TransplantationH W Auner, R Szydlo, A van Biezen, et al.
Pageof 14

Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
Journal of Internal Medicine|October 30, 2018
Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysisJ Canaani, E Beohou, M Labopin, et al.
Annals of Hematology|September 22, 2016
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMTE M P Cremers, A van Biezen, L C de Wreede, et al.
Bone Marrow Transplantation|July 28, 2009
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMTY Chalandon, J R Passweg, C Schmid, et al.
Journal of Internal Medicine|October 14, 2017
What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?O Ringdén, M Labopin, B Sadeghi, et al.
Leukemia|July 17, 1998
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia GroupE Elonen, A Almqvist, A Hänninen, et al.
Bone Marrow Transplantation|January 27, 2004
Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmesS McCann, J L Byrne, M Rovira, et al.
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†S P Robinson, A Boumendil, H Finel, et al.
Bone Marrow Transplantation|June 2, 2015
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMTJ R Passweg, M Labopin, J Cornelissen, et al.
Bone Marrow Transplantation|May 28, 2013
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow TransplantationH W Auner, R Szydlo, A van Biezen, et al.
Pageof 14